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STUDY PROTOCOL Open Access
Metabolic follow-up at one year and beyond
of women with gestational diabetes treated
with insulin and/or oral hypoglycaemic
agents: study protocol for the identification
of a core outcomes set using a Delphi survey
Delia Bogdanet1* , Aoife Egan1, Narjes Fhelelboom1, Linda Biesty1, Shakila Thangaratinam2, Eugene Dempsey3,
Caroline Crowther4, Declan Devane1 and Fidelma Dunne1
Abstract
Background: Gestational diabetes (GDM) is associated with an increased lifetime risk for the development of
glucose abnormalities, metabolic syndrome, cardiovascular disease, depression and tumours. Despite this high risk
of additional comorbidities, there is no standardised approach to the long-term follow-up of women with a
previous diagnosis of GDM. Also, there is no standardisation of outcome selection and reporting in studies
involving this population. This increases the risk of reporting bias and reduces the possibility of meaningful
comparisons between studies. The aim of this study is to develop a protocol for a core outcome set (COS) for the
metabolic follow-up at 1 year and beyond of women with previous GDM treated with insulin and/or oral
hypoglycaemic agents.
Methods/design: This protocol will describe the steps that will be taken in order to develop the COS. The study
will consist of three parts: (1) A systematic review of the literature of the outcomes reported in previous
randomised controlled trials of the follow-up at 1 year and beyond of women with GDM treated with insulin and/
or oral hypoglycaemic agents; (2) A three-round, online Delphi survey with key stakeholders in order to prioritise
these outcomes; and (3) A consensus meeting where the final COS will be decided.
Discussion: The proposed protocol is the first step in developing a COS that will bring consistency and uniformity
to outcome selection and reporting in GDM women treated with insulin and/or oral hypoglycaemic agents.
Keywords: Core outcome set, Gestational diabetes, Insulin, Oral hypoglycaemic agents
Background
In Europe, the prevalence of gestational diabetes (GDM)
is approximately 13% [1, 2]. Medical nutritional therapy
is the keystone of treating GDM as it maintains desired
glycaemic goals in 80–90% of GDM women [3]. The
remaining 10–20% will require insulin and/or oral
hypoglycaemic agents.
GDM is associated with a significant lifetime risk of
progression to type 2 diabetes. A meta-analysis of cohort
studies conducted over the last 40 years showed a rela-
tive risk of 7.7 for the future development of type 2 dia-
betes (T2DM) in women with a history of GDM
compared with women with normal glucose tolerance
(NGT) in pregnancy [4]. Women with previous GDM
are at risk of developing metabolic syndrome [5] and
cardiovascular disorder [6] in later life. Some studies
show increased postpartum depression among women
with GDM [7, 8]. There is also an increasing body of lit-
erature associating a previous diagnosis of GDM with
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the development of tumours, particularly breast and
endometrial tumours [9, 10].
Because GDM may represent pre-existing undiagnosed
type 2 diabetes, women with GDM should be screened
for persistent diabetes or prediabetes at 6–12 weeks
postpartum using nonpregnancy criteria and every 1–3
years thereafter depending on risk factors [11]. However,
there is no standardised approach to the long-term
follow-up of women with a previous diagnosis of GDM.
More so, there is no standardisation of outcome selec-
tion and reporting in studies involving this population.
Development of a core outcome set
A core outcome set (COS) defines the minimum set of
outcomes that should be consistently measured and re-
ported in clinical trials. The existence of a COS does not
mean that only these outcomes should be measured.
However, a minimum, or core, set of outcomes will pro-
vide greater consistency of reporting in clinical trials and
more evidence to contribute to meta-analyses. Also, this
will reduce the risk of reporting bias by consistently
measuring and reporting these outcomes.
The outcomes relevant to post-pregnancy care are
numerous and include both maternal and child out-
comes. There is significant diversity in the outcomes
measured and reported in the studies evaluating
long-term follow-up of women with a previous diagnosis
of GDM. This heterogeneity in outcomes is highlighted
in a Cochrane systematic review evaluating the effects of
exercise or exercise and diet on preventing T2DM [12].
Orozco and colleagues noted that of eight studies only
six recorded the Body Mass Index (BMI), only four re-
corded the waist to hip ratio (WHR), five recorded the
total cholesterol value and six recorded blood pressures.
Fig. 1 Study process
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This variation in outcome selection makes comparison
and synthesis of work difficult and amplifies the bias
whereby researchers might select outcomes that only an-
swers one research question and report only favourable
results [13, 14]. A COS will facilitate the comparison
and facilitate the synthesis of appropriate studies. The
development of such COS is facilitated and supported
by the Core Outcome Measures in Effectiveness Trials
Initiative (COMET), which was launched in 2010 and
brings together researchers interested in the develop-
ment, application and promotion of COS while minimis-
ing duplication of effort [15]. In 2014, the editors of over
50 journals began the Core Outcomes in Women’s and
Newborn Health (CROWN) [16, 17] initiative, the pur-
pose of which is to encourage researchers to develop
COSs, report the results of the core outcome sets and
facilitate embedding of COS in clinical practice.
Another important argument for the development of
COS is that outcomes reported for trials may not reflect
the endpoints important for health service users. In pre-
vious studies, patients identified outcomes important to
them, outcomes that might not have been considered by
clinicians [18–20].
Study aim
The aim of this article is to present a protocol for a
study to develop a COS for trials and other studies in
the follow-up at 1 year and beyond of women with ges-
tational diabetes treated with insulin and/or oral
hypoglycaemic agents. This study focusses only on
women with GDM treated with insulin and oral
hypoglycaemic agents as this population has more glu-
cose abnormalities and is more likely to progress to
T2DM, obesity and metabolic syndrome.
Methods/design
Ethics: ethical approval to conduct this study was sought
and obtained from the Ethics Committee at Galway Uni-
versity Hospitals (home institution of the study’s princi-
pal investigator).
Part 1: Systematic review to generate a list containing
possible relevant outcomes
Systematic review question
What are the outcomes reported in clinical trials of the
follow-up at 1 year and beyond of women with gesta-
tional diabetes treated with insulin and/or oral
hypoglycaemic agents?
Methods
Using a broad-based search strategy, the following data-
bases will be searched for relevant studies: the Cochrane
Central Register of Controlled Trials (CENTRAL), the
Cumulative Index to Nursing and Allied Health
Literature (CINAHL), PubMed, Embase and Web of Sci-
ence. ClinicalTrials.gov will also be searched for relevant,
ongoing trials. The advantages conferred by using CEN-
TRAL in addition to the other databases are that trials
from other sources of research are hand searched, and
controlled trials from these are included. This improves
the chances of identifying all relevant studies. Key terms
used to guide the search will include ‘gestational dia-
betes’, ‘GDM’, ‘insulin’, ‘oral hypoglycaemic’, ‘oral antihyper-
glycaemic’, ‘treatment’, ‘pharmacological’, ‘medication’,
‘antidiabetic’, ‘metformin’ ‘glyburide’,’ outcome’, ‘follow-up’
and ‘postpartum’ combined as appropriate using the
Boolean operands ‘AND’ and ‘OR’. There are no date re-
strictions for study inclusion. An example for the search
strategy has been provided in the Additional file 1.
The reference lists of all relevant studies will be
searched for additional relevant studies not retrieved
from the electronic database search. Language restric-
tions will not be applied to the search strategy; however,
selection of relevant articles will be restricted to English
language publications. Searching all languages will en-
able us to identify the extent of potentially eligible add-
itional studies that will not be included and consider if
this presents a source of language bias.
Types of studies
Including all types of studies will generate an extremely
large list and seeing that clinical trials are more likely to
have clearly defined outcomes, we will only include ran-
domised control trials (RCTs) and RCT follow-up stud-
ies in our systematic review. Studies by any other design
other than RCT will be excluded. In line with prior work
in this area, we will also exclude review reports and re-
ports of conference proceedings, studies with less than
10 participants or abstracts when their complete de-
scription of the trial or study is absent.
Types of participants
Participants will be women with previously diagnosed
gestational diabetes by any internationally agreed criteria
(the World Health Organisation (WHO),the Inter-
national Association of the Diabetes and Pregnancy
Study Groups (IADPSG), the National Institute for
Health and Care Excellence (NICE), Carpenter and
Coustan, the American Diabetes Association (ADA),the
American College of Obstetricians and Gynaecologists
(ACOG), The National Diabetes Data Group (NDDG),
Hyperglycemia and Adverse Pregnancy Outcome
(HAPO), O’Sullivan and Mahan) treated with insulin
and/or oral hypoglycaemic agents in the index follow-up
period. We will not restrict the search to any particular
screening or diagnosing criteria for gestational diabetes
to increase usefulness of the COS internationally.
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Exclusion criteria
Exclusion criteria will include studies of women with a
pre-pregnancy diagnosis of diabetes and studies that
only include participants treated with medical nutritional
therapy only.
Study assessment
An initial selection of studies identified in the search will
be performed using the predetermined review inclusion
criteria. Due to the absence of a study design filter, we ex-
pect that a large number of records will be identified by
our search strategy. In the first step, all identified study ti-
tles will be reviewed and ineligible studies excluded (FPD
and DB). In the second step of the review, the remaining
studies will be reviewed by two reviewers (FPD and DB)
who will independently assess the titles and abstracts of
studies included at this stage. Full texts of studies meeting
the inclusion criteria, or where there is uncertainty regard-
ing inclusion at title and abstract screening, will be re-
trieved and reviewed independently by two authors (FPD
and DB) with final decisions on inclusion or exclusion
achieved through consensus. In cases of disagreement, a
third independent reviewer will be consulted (DD).
Data extraction
Outcomes will be identified within the ‘Methods’ and
‘Results’ sections of each paper and for each outcome we
will assess how it was defined and measured, the defin-
ition used, the number of participants in which it was
measured, the indicators and/or tools used to measure
the outcomes, the time points or periods of outcome
measurement and whether it was stated in both the
methods and results. Additional data that will be ex-
tracted includes: study design, author details, year and
journal of publication. The individual outcomes will be
categorised under broader outcome domains.
Two review authors (FPD and DB) will extract data in-
dependently, review the data together, assess consensus
and ensure that all outcomes have been identified.
Disagreement will be resolved through discussion.
Where a resolution is not possible, a third reviewer will
be consulted.
Data analysis
All eligible studies will be tabulated and the identified
outcomes presented along with their definitions. We
wish to establish whether outcomes are defined and, if
they are, whether there is a difference in defining terms
between studies which would make comparison of these
outcomes between trials more difficult.
All outcomes identified in the studies will be included.
These outcomes will be categorised under appropriate
outcome domains which will be decided upon by the au-
thors. Within each domain, we will be able to evaluate
both how many different outcomes have been used to re-
flect that domain and the frequency of selection for each
individual outcome, and the times at which they were
measured will be documented. The outcome domains will
be reviewed by the Study Advisory Group (SAG) to assess
suitability of the domain name and grouping of outcomes.
The SAG will include representatives from researchers,
healthcare professionals and patients.
Part 2: Developing a consensus on outcomes important
to different stakeholders using a Delphi survey and
consensus meeting
Delphi survey
We will use a Delphi survey to develop consensus on
the most important outcomes from those identified in
the systematic review [21]. The Delphi survey was devel-
oped originally by the RAND Corporation in the 1950s
in order to forecast the influence of technology on war-
fare [22]. It is an iterative consensus technique, which
comprises successive questionnaires answered by a panel
of participants with relevant expertise. Questioning takes
place in rounds, and after each round of questions, an
anonymous summary of the responses is fed back to the
group. Individual participants may then decide to keep
their original answers or to change their opinion in the
subsequent round. Participants will not be able to iden-
tify other participants or individual responses.
This technique has the advantage over a roundtable
meeting in that it can avoid the situation where certain
individuals can dominate a discussion or where other in-
dividuals feel obliged to agree with the opinions of more
senior members. It also facilitates wide international par-
ticipation and increased numbers of stakeholders
informing the prioritisation process. To improve effi-
ciency, the questionnaire will be completed online using
an appropriate software for online survey design.
The list of potential outcomes finalised in part 1 will
be formatted into a list of outcomes with a response de-
signed to allow the participants to rate each one of the
outcomes on a 9-point Likert-type scale, with higher
values representing increased importance for inclusion
of the outcome in the COS. Following review of the out-
come list by the research group (DB, AE, NF, LB, CC,
DD and FPD), the list will be circulated to the SAG. The
SAG, composed of key stakeholders, will be asked to
comment on the overall list of outcomes and the suit-
ability of the domains under which they are grouped.
They will additionally be asked to list any other out-
comes that they think should be included. These other
outcomes will be added to the list for inclusion in the
Delphi survey. Members of the SAG will not participate
in the Delphi exercise, as they had a role in study design,
which may influence scoring. Instead, they will be in-
vited to participate in the final consensus meeting.
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Participants
The panel of participants includes:
 Women (service users); they will have had a
diagnosis of gestational diabetes and will have been
treated with insulin and/or oral hypoglycaemic
agents for this diagnosis. Recruitment will include
listed groups of diabetes services users (e.g. Diabetes
Ireland) accessed via the electronic discussion email
list manager. The manager will be emailed
information on the survey with a request to
distribute an invitation email to members on their
email lists. The list managers will have an
opportunity to contact the researcher directly to
clarify any issues or to seek further information
about the survey and the research before deciding.
The distribution of the survey will be at the
discretion of the email list manager. Clinicians will
also be asked to invite service users to participate via
their pregnancy and diabetes care clinical teams
 Clinicians will include endocrinologists,
obstetricians, paediatricians, neonatologists, general
practitioners and practice nurses, diabetic nurses,
midwives, dieticians and physiotherapists
 Researchers with expertise in diabetes care from
DPSG (Diabetes in Pregnancy Study Group),
IADPSG, FIGO (International Federation of
Gynaecology and Obstetrics) and EBCOG
(European Board and College of Obstetrics and
Gynaecology) will be invited to participate
 Policy-makers from the HSE (Healthcare Service
Executive), IDF (International Diabetes Federation)
and WHO (World Health Organisation) will also be
invited to participate
Clinicians and researchers will be invited from na-
tional and international specialist centres. Clinical
leads will be identified and recruited through the
DPSG, which is a study group of the European Associ-
ation for the Study of Diabetes (EASD), IADPSG,
FIGO and EBCOG. Clinicians will also be identified
through journal email lists, national training bodies
and national diabetes societies. Clinical leads will be
invited to participate by email and will be asked to for-
ward the study details to other members of their preg-
nancy care teams.
Participants from all the above groups will be asked
to forward the invitation to others whom they regard
as having the required expertise. Although there is
currently no standard method for sample size calcula-
tion in the Delphi process, we will aim for a total of
180 participants, including at least 30 service users.
Efforts will be taken to maximise the response rate
across stakeholder groups.
Each participant will be emailed an invitation outlining
the study, its importance and a link to the online survey.
Informed consent to participate in the study will be ob-
tained from each participant when registering for the on-
line Delphi questionnaire. The consent process will take
place before any answer is submitted. We will underline
the importance of completing the whole Delphi survey
process, and generic reminder emails will be sent to aid
completion of each round. A unique identifier will be
assigned to each participant, tracked to their email address,
which will allow monitoring of attrition at each round.
Delphi study round 1
The online questionnaire will request the participant’s
name, email address and centre with to which they are
aligned. Participants will be asked to identify the stake-
holder group and subgroup to which they belong. They
will be asked to complete the questionnaire within 3
weeks. A reminder email will be sent the end of week 2
to prompt completion of the survey.
The questionnaires will contain lay terminology along-
side clinical terms to assist women in understanding
complex terminology. The list of outcomes to be scored
will be ordered alphabetically to avoid weighting of out-
comes caused by the order in which they are displayed.
There will be an option for a participant to add up to
two additional outcomes not already included together
with a score for each outcome added.
Participants will be asked to score each of the out-
comes listed using the Grading of Recommendations As-
sessment, Development and Evaluation (GRADE) scale
which involves a 9-point scale to rank importance.
Scores will be grouped into 1–3 = limited importance,
4–6 = important but not critical or 7–9 = critical.
Analysis of round 1
The results of round 1 will be summarised using descrip-
tive statistics, including the proportion of participants
from each stakeholder group scoring for each rating point
on the Likert scale (i.e. for each point from 1 to 9). The
additional outcomes listed will be reviewed by the re-
searchers (FPD and DB). If they have been proposed by
two or more participants and if they are deemed to repre-
sent a new outcome based on this review, they will be in-
cluded for round 2 and the SAG will be consulted to
review if appropriate. All outcomes will be carried forward
to the second round with first round scores displayed for
each outcome and the distribution of scores from each
stakeholder group. Continuation to round 2 will be con-
sidered based on the response to round 1. If a low number
of responders (< 10) is observed for one or more stake-
holder groups, the Delphi protocol for future rounds will
be reviewed and revised. If there is only one stakeholder
group with a small number of respondents, then that
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group may be classified together with another stakeholder
group following consultation with the SAG to ensure
appropriateness of grouping.
Delphi study round 2
Participants who respond to round 1 will be forwarded
the round 2 questionnaire and asked to complete it on-
line. Each participant will be presented with the number
of respondents and distribution of scores for each out-
come per stakeholder group. They will also be shown
their score from round 1, asked to consider responses
from the other members of the stakeholder groups and
invited to re-score the outcome.
Analysis of round 2
The total number of participants invited to take part in
round 2 will be recorded. The results of round 2 will be
summarised using descriptive statistics. For each out-
come, the number of participants who have scored the
outcome and the distribution of scores will be noted.
Consensus to carry an outcome through to the COS will
be defined as more than 70% of participants scoring its
importance as 7–9 and less than 15% scoring it as 1–3.
Delphi study round 3
Participants who respond to rounds 1 and 2 will be for-
warded the round-3 questionnaire and asked to
complete it online. Again, each participant will be pre-
sented with the number of respondents and distribution
of scores for each outcome for each stakeholder groups.
They will also be shown their score from round 2, asked
to consider responses of other members of the stake-
holder group and asked to re-score the outcomes.
Analysis of round 3
The total number of participants taking part will be re-
corded. The results of round 3 will be summarised using
descriptive statistics. For each outcome, the number of
participants who have scored the outcome and the distri-
bution of scores from each stakeholder group will be
noted. Consensus to carry an outcome through to the
COS will be defined as more than 70% of participants
scoring its importance as 7–9 and less than 15% scoring it
as 1–3. Each outcome will be classified as ‘consensus in’,
‘consensus out’ or ‘no consensus’. Although these cut-offs
are subjective, they have previously been described in a
COS protocol [23] and are prespecified here.
Consensus group meeting
Methods
This final phase will involve a face-to-face meeting with
key stakeholders. The meeting participants will be selected
to ensure that all stakeholder groups are represented rea-
sonably. The participants will be invited from among those
who completed all rounds of the Delphi study. The results
obtained from each round of the Delphi survey will be pre-
sented. The objective of the consensus meeting is to dis-
cuss outcomes on which there were incongruous opinions
in round 3 of the Delphi study and to agree on a list of final
outcomes which will constitute the COS. Discussion of
each reporting item will be followed by an anonymous
scoring method by those at the consensus meeting. Similar
to the Delphi stage, items will be considered as ‘consensus
in’ if 70% of the consensus meeting participants vote in
favour of the item to be included in the COS. The meeting
will also agree on publication and dissemination strategies.
Participants
The consensus group will include 10–20 participants
and members of the SAG. A half-day meeting is planned
to achieve effective consensus. The facilitator will ensure
that the meeting is collaborative, egalitarian, comprehen-
sive and participatory. A flow diagram of the study
methods has been provided in Fig 1.
Discussion
There is currently no COS for studies assessing the
follow-up of women diagnosed with gestational diabetes
treated with insulin/oral hypoglycaemic agents. The aim of
development of such a COS in this clinical area is to im-
prove the interpretation and comparison of future studies
while reducing the risk of outcome reporting bias and het-
erogeneity between studies. We will involve key stakeholders
and use recognised techniques to ensure that the resulting
COS is suitable and accepted in future research studies.
Study status
The study plan is to complete the systematic review by
December 2017 and development of the COS by
October 2018.
Additional file
Additional file 1: Search strategy examples. (DOCX 14 kb)
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